<DOC>
	<DOCNO>NCT01591668</DOCNO>
	<brief_summary>Dose cohort may dose one 4 possible total weekly dos ( 0.3 mg , 1 mg , 2 mg , 4 mg ) . Dose escalation repetition govern pre-specified safety activity rule . Subjects confine either day 1-3 and/or day 8-10 . Follow-up visit also require periodically day 43 . Study procedure involve take blood sample pharmacokinetic , pharmacodynamic , virologic , safety assessment .</brief_summary>
	<brief_title>A Study Evaluating GS-9620 Treatment Naive Subjects With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Males Females 1865 year old Chronic HCV infection least 6 month , treatment naive HCV Viral load &gt; 100,000 IU/mL Screening Monoinfection HCV 1 genotype Hepatitis B surface antigen negative Screening ECG without clinically significant abnormality BMI 1833 kg/m^2 Creatinine clearing &gt; 70 mL/min Negative pregnancy test screening Pregnant lactating subject Coinfection hepatitis B virus ( HBV ) HIV History Gilberts disease Particular abnormal laboratory parameter Diagnosis autoimmune disease , poorly control diabetes , significant psychiatric illness , severe chronic obstructive pulmonary disease ( COPD ) , malignancy , hemoglobinopathy , retinal disease , immunosuppressed Evidence hepatocellular carcinoma Ongoing alcohol abuse Positive uring drug screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Chronic HCV</keyword>
	<keyword>HCV</keyword>
	<keyword>Treatment Naive</keyword>
	<keyword>Gilead</keyword>
	<keyword>GS-9620</keyword>
</DOC>